IO Biotech Appoints Kathleen Sereda Glaub as Member of Board of Directors

Jun 6, 2018

Copenhagen, Denmark – June 6, 2018: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win technology, today announced the appointment of Kathleen Sereda Glaub, MBA, as member of the Board of Directors.

Other news

IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

IO Biotech Announces Third Quarter Results for 2022

IO Biotech Announces Third Quarter Results for 2022